The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial EXTENDed Follow-up (EXTEND)

医疗和侵入性方法的比较健康有效性国际研究 (ISCHEMIA) 试验延长随访 (EXTEND)

基本信息

项目摘要

PROJECT SUMMARY/ ABSTRACT The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) EXTENDed Follow-up (EXTEND) is the long-term follow-up of randomized, surviving participants in ISCHEMIA. This NHLBI-supported trial randomized 5,179 participants with stable ischemic heart disease to two different management strategies: 1) an initial invasive strategy (INV) of cardiac catheterization and revascularization when feasible plus guidelines-based medical therapy (GBMT), or 2) an initial conservative strategy of GBMT. The trial did not demonstrate a reduction in the primary endpoint with an initial invasive strategy. There was an excess of peri-procedural myocardial infarction (MI) and a reduction in spontaneous MI in the INV group. Prior evidence demonstrates that spontaneous MI carries a higher risk of subsequent death than peri-procedural MI. There was a late separation in the cardiovascular (CV) mortality curves, over a median of 3.2 years follow-up in ISCHEMIA. The overall reduction in MI rates with an INV strategy did not emerge until after 2 years. Therefore, based on the observed reduction in spontaneous MI, it is imperative to ascertain long-term vital status to provide patients and clinicians with robust evidence on whether INV strategy reduces CV and all-cause death over the long-term. With projected 728 CV deaths (1000 total) we have adequate power to detect a between group difference. It is equally important to improve precision around the point estimate to rule out a benefit if none exists. Regardless of the study findings, robust long-term mortality data have enormous implications for clinical guidelines and practice, as affirmed by independent experts who write and oversee the development of national guidelines, and who provided letters of support. We will also quantify the impact of nonfatal CV events on subsequent mortality in ISCHEMIA-EXTEND, construct a risk score for mortality using baseline deep phenotypic data, and provide estimates of the impact of INV in the highest risk subgroup – those with severe coronary artery disease for whom current practice guidelines recommend coronary artery bypass (CABG) to improve survival. We have obtained all required approvals and 99% of consents. We are ready to conduct extended follow-up of death, including cause of death, on >99% of surviving participants resulting in 10-year median follow-up. We will ascertain vital status by participant/proxy contact every 6 months via telephone or email, or by searching high-quality national/regional health/death databases. Participant last contact date, date of death, cause of death, and source of information will be collected and entered into a web-based electronic data capture system. Our excellent participant retention, adherence to protocol, data completeness and quality during the initial trial phase, and our subsequent progress, with required approvals and consents secured, assure confidence that the study will meet its goals.
项目摘要/摘要 医学方法和侵入性方法健康效果比较的国际研究 (缺血)延长随访(EXTEND)是对随机、存活的参与者的长期随访 在缺血状态下。这项由NHLBI支持的试验随机选择了5,179名患有稳定型缺血性心脏病的患者 两种不同的管理策略:1)心导管的初始有创策略(INV)和 可行的血运重建加以指南为基础的药物治疗(GBMT),或2)最初的保守治疗 GBMT战略。这项试验没有显示初始有创手术的主要终点的减少 策略。围手术期心肌梗死(MI)增多,自发性MI减少 在INV组。先前的证据表明,自发性心肌梗死具有更高的后续死亡风险 而不是围手术期心肌梗死。在心血管(CV)死亡率曲线上有一个较晚的分离,超过一年 缺血的中位随访时间为3.2年。INV策略对MI率的总体降低并没有 直到两年后才会出现。因此,基于观察到的自发MI的减少,迫切需要 确定长期生命状态,为患者和临床医生提供关于INV策略是否有效的有力证据 从长远来看,减少简历和各种原因造成的死亡。预计有728例心血管疾病死亡(总计1000例) 有足够的功率来检测组之间的差异。同样重要的是,提高 点估计以排除福利(如果不存在)。不管研究结果如何,稳健的长期死亡率 数据对临床指南和实践具有巨大的影响,正如独立专家所确认的那样, 撰写和监督国家指导方针的制定,以及谁提供了支持信。我们还将 量化非致命性心血管事件对缺血后死亡率的影响-扩展,构建风险 使用基线深层表型数据对死亡率进行评分,并提供对INV在 最高风险亚组-那些患有严重冠状动脉疾病的人,目前的实践指南 推荐冠状动脉搭桥术(CABG)以提高存活率。我们已经获得了所有必要的批准和 99%的人同意。我们准备对99%的人进行更长时间的死亡跟踪,包括死亡原因 存活的参与者获得了10年的中位随访期。我们将通过参与者/代理来确定重要状态 每6个月通过电话或电子邮件联系,或通过搜索高质量的国家/地区健康/死亡 数据库。参与者最后一次联系日期、死亡日期、死因和信息来源 收集并输入以网络为基础的电子数据采集系统。我们优秀的参与者留存率, 在最初的试验阶段和我们的后续试验阶段遵守协议、数据完整性和质量 在获得所需批准和同意的情况下,取得了进展,确保了这项研究将实现其目标的信心。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Judith S Hochman其他文献

1118-102 Baseline white blood cell count and interleukin-6 levels provide complementary prognostic information in acute myocardial infarction: Results from the CARDINAL trial
  • DOI:
    10.1016/s0735-1097(04)91234-x
  • 发表时间:
    2004-03-03
  • 期刊:
  • 影响因子:
  • 作者:
    Manesh R Patel;Kenneth W Mahaffey;Paul W Armstrong;W.Douglas Weaver;Gudaye Tasissa;Judith S Hochman;Thomas G Todaro;Kevin J Malloy;Thomas H Parish;Scottt Rollins;Pierre Theroux;Wiltold Ruzyllo;Jose C Nicolau;Christopher B Granger
  • 通讯作者:
    Christopher B Granger
869-4 Sex disparities in the treatment of non-ST-segment elevation acute coronary syndromes
  • DOI:
    10.1016/s0735-1097(04)91286-7
  • 发表时间:
    2004-03-03
  • 期刊:
  • 影响因子:
  • 作者:
    Andra L Blomkalns;L.Kristin Newby;Anita Chen;Eric D Peterson;Kelly Trynosky;Deborah Diercks;William E Boden;Matthew T Roe;E.Magnus Ohman;W.Brian Gibler;Judith S Hochman
  • 通讯作者:
    Judith S Hochman
861-1 Direct, selective, factor Xa inhibition in patients with non-ST elevation acute coronary syndromes from the United States, Canada, and Japan: Results of the XaNADU-ACS trial
  • DOI:
    10.1016/s0735-1097(04)91279-x
  • 发表时间:
    2004-03-03
  • 期刊:
  • 影响因子:
  • 作者:
    John H Alexander;Hongqiu Yang;Richard C Becker;Kazuhisa Kodama;Christopher K Dyke;Shaun G Goodman;Neal S Kleiman;Judith S Hochman;Peter B Berger;Eric A Cohen;Michael Lincoff;Edwin G Bovill;Chuichi Kawai;Paul W Armstrong;Robert A Harrington
  • 通讯作者:
    Robert A Harrington

Judith S Hochman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Judith S Hochman', 18)}}的其他基金

The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial EXTENDed Follow-up (EXTEND)
医疗和侵入性方法的比较健康有效性国际研究 (ISCHEMIA) 试验延长随访 (EXTEND)
  • 批准号:
    10379246
  • 财政年份:
    2021
  • 资助金额:
    $ 191.12万
  • 项目类别:
The Ischemia Trial - CCC
缺血试验 - CCC
  • 批准号:
    8735224
  • 财政年份:
    2011
  • 资助金额:
    $ 191.12万
  • 项目类别:
The Ischemia Trial - CCC
缺血试验 - CCC
  • 批准号:
    8434047
  • 财政年份:
    2011
  • 资助金额:
    $ 191.12万
  • 项目类别:
The Ischemia Trial - CCC
缺血试验 - CCC
  • 批准号:
    9067491
  • 财政年份:
    2011
  • 资助金额:
    $ 191.12万
  • 项目类别:
The Ischemia Trial - CCC
缺血试验 - CCC
  • 批准号:
    8306047
  • 财政年份:
    2011
  • 资助金额:
    $ 191.12万
  • 项目类别:
The Ischemia Trial - CCC
缺血试验 - CCC
  • 批准号:
    8032675
  • 财政年份:
    2011
  • 资助金额:
    $ 191.12万
  • 项目类别:
Occluded Artery Trial: Long Term Follow-Up
动脉闭塞试验:长期随访
  • 批准号:
    7301705
  • 财政年份:
    1999
  • 资助金额:
    $ 191.12万
  • 项目类别:
Occluded Artery Trial: Long Term Follow-Up
动脉闭塞试验:长期随访
  • 批准号:
    7871492
  • 财政年份:
    1999
  • 资助金额:
    $ 191.12万
  • 项目类别:
OCCLUDED ARTERY TRIAL--CLINICAL COORDINATING CENTER
动脉闭塞试验--临床协调中心
  • 批准号:
    7225839
  • 财政年份:
    1999
  • 资助金额:
    $ 191.12万
  • 项目类别:
OCCLUDED ARTERY TRIAL--CLINICAL COORDINATING CENTER
动脉闭塞试验--临床协调中心
  • 批准号:
    6527429
  • 财政年份:
    1999
  • 资助金额:
    $ 191.12万
  • 项目类别:

相似海外基金

Linking Epidermis and Mesophyll Signalling. Anatomy and Impact in Photosynthesis.
连接表皮和叶肉信号传导。
  • 批准号:
    EP/Z000882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 191.12万
  • 项目类别:
    Fellowship
Digging Deeper with AI: Canada-UK-US Partnership for Next-generation Plant Root Anatomy Segmentation
利用人工智能进行更深入的挖掘:加拿大、英国、美国合作开发下一代植物根部解剖分割
  • 批准号:
    BB/Y513908/1
  • 财政年份:
    2024
  • 资助金额:
    $ 191.12万
  • 项目类别:
    Research Grant
Simultaneous development of direct-view and video laryngoscopes based on the anatomy and physiology of the newborn
根据新生儿解剖生理同步开发直视喉镜和视频喉镜
  • 批准号:
    23K11917
  • 财政年份:
    2023
  • 资助金额:
    $ 191.12万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetics of Extreme Phenotypes of OSA and Associated Upper Airway Anatomy
OSA 极端表型的遗传学及相关上呼吸道解剖学
  • 批准号:
    10555809
  • 财政年份:
    2023
  • 资助金额:
    $ 191.12万
  • 项目类别:
computational models and analysis of the retinal anatomy and potentially physiology
视网膜解剖学和潜在生理学的计算模型和分析
  • 批准号:
    2825967
  • 财政年份:
    2023
  • 资助金额:
    $ 191.12万
  • 项目类别:
    Studentship
Computational comparative anatomy: Translating between species in neuroscience
计算比较解剖学:神经科学中物种之间的翻译
  • 批准号:
    BB/X013227/1
  • 财政年份:
    2023
  • 资助金额:
    $ 191.12万
  • 项目类别:
    Research Grant
Doctoral Dissertation Research: Social and ecological influences on brain anatomy
博士论文研究:社会和生态对大脑解剖学的影响
  • 批准号:
    2235348
  • 财政年份:
    2023
  • 资助金额:
    $ 191.12万
  • 项目类别:
    Standard Grant
Development of a novel visualization, labeling, communication and tracking engine for human anatomy.
开发一种新颖的人体解剖学可视化、标签、通信和跟踪引擎。
  • 批准号:
    10761060
  • 财政年份:
    2023
  • 资助金额:
    $ 191.12万
  • 项目类别:
Understanding the functional anatomy of nociceptive spinal output neurons
了解伤害性脊髓输出神经元的功能解剖结构
  • 批准号:
    10751126
  • 财政年份:
    2023
  • 资助金额:
    $ 191.12万
  • 项目类别:
The Anatomy of Online Reviews: Evidence from the Steam Store
在线评论剖析:来自 Steam 商店的证据
  • 批准号:
    2872725
  • 财政年份:
    2023
  • 资助金额:
    $ 191.12万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了